PPIDT00207

Drug Information
NameTelavancin
SequenceNot Available
DrugBank_IDDB06402
Typesmall molecule
IndicationFor the treatment of complicated skin and skin structure infections (cSSSI) caused by gram-positive bacteria like methicillin-susceptible or -resistant Staphylococcus aureus, vancomycin-susceptible Enterococcus faecalis, and Streptococcus pyogenes, Streptococcus agalactiae, or Streptococcus anginosus group. Also for the treatment of adult patients with hospital-acquired bacterial pneumonia (HAP) and ventilator-associated bacterial pneumonia (VAP), known or suspected to be caused by susceptible isolates of Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant S. aureus).

Dosage Forms
Form Route Strength
Injection, powder, for solution Intravenous
Injection, powder, for solution Intravenous
250 mg
Injection, powder, for solution Intravenous
750 mg
Injection, powder, lyophilized, for solution Intravenous
15 mg/1mL
Injection, powder, lyophilized, for solution Intravenous
250 mg/1
Injection, powder, lyophilized, for solution Intravenous
750 mg/1
Powder, for solution Intravenous
250 mg / vial
Powder, for solution Intravenous
750 mg / vial
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target Q15822 CHRNA2 Neuronal acetylcholine receptor subunit alpha-2 Homo sapiens agonist Link
target P32297 CHRNA3 Neuronal acetylcholine receptor subunit alpha-3 Homo sapiens agonist Link
target P34998 CRHR1 Corticotropin-releasing factor receptor 1 Homo sapiens antagonist Link